Duality Biotherapeutics, Inc.
Cena
Finančné výkazy zatiaľ nemáme
Firma vykazuje v mene CNY, cena titulu je v mene HKD. Výkazy zatiaľ neprevádzame medzi menami, pretože by z nich násobky (P/E, P/S a ďalšie) vychádzali nesprávne, a preto ich tu neukazujeme. Cenu a jej vývoj vidíte vyššie.
Fundamenty
Načítavam kľúčové čísla…
Insideri, analytici a ľudia
Všetky obchody a zmenyNačítavam insiderov, analytikov a názory…
Co se právě děje
AI souhrnO spoločnosti
Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others in China and internationally. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stage ADCs. It has strategic partnerships with BioNTech SE to develop therapies to complement or replace chemotherapy; BeOne to develop and commercialize DB-1312, an in-house discovered B7-H4- targeted ADC; and Genentech, Inc. to develop antibody-drug conjugates. The company was incorporated in 2019 and is headquartered in Shanghai, China.
Český popis pripravujeme.
- Zamestnanci
- 266
- Krajina
- Čína
- Dáta od
- 15. 4. 2025